Aktienanalyse zu Aurinia Pharmaceuticals Inc. (AUPH)AUPHAurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aurinia Pharmaceuticals Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $16.51, and the company has shown a 39.44% increase over the past year. Additionally, the gross margin has improved to 92.12% in Q2 2026, indicating strong profitability. The main risk is the forward P/E ratio of 11.83, which suggests that the stock may be overvalued if growth expectations are not met.

5 analysts cover AUPH: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 16.50.